Timosaponin AⅢ induces drug-metabolizing enzymes by activating constitutive androstane receptor (CAR) via dephosphorylation of the EGFR signaling pathway

Abstract

The current study aimed to assess the effect of timosaponin AⅢ (T-AⅢ) on drug-metabolizing enzymes during anticancer therapy. The in vivo experiments were conducted on nude and ICR mice. Following a 24-day administration of T-AⅢ, the nude mice exhibited an induction of CYP2B10, MDR1, and CYP3A11 expression in the liver tissues. In the ICR mice, the expression levels of CYP2B10 and MDR1 increased after a three-day T-AⅢ administration. The in vitro assessments with HepG2 cells revealed that T-AⅢ induced the expression of CYP2B6, MDR1, and CYP3A4, along with constitutive androstane receptor (CAR) activation. Treatment with CAR siRNA reversed the T-AⅢ-induced increases in CYP2B6 and CYP3A4 expression. Furthermore, other CAR target genes also showed a significant increase in the expression. The up-regulation of murine CAR was observed in the liver tissues of both nude and ICR mice. Subsequent findings demonstrated that T-AⅢ activated CAR by inhibiting ERK1/2 phosphorylation, with this effect being partially reversed by the ERK activator t-BHQ. Inhibition of the ERK1/2 signaling pathway was also observed in vivo. Additionally, T-AⅢinhibited the phosphorylation of EGFR at Tyr1173 and Tyr845, and suppressed EGF-induced phosphorylation of EGFR, ERK, and CAR. In the nude mice, T-AⅢ also inhibited EGFR phosphorylation. These results collectively indicate that T-AⅢ is a novel CAR activator through inhibition of the EGFR pathway.

Keywords

timosaponin AⅢ / CAR / metabolism enzyme / ERK1/2 signaling pathway / EGFR signaling pathway

Fundings

This study was supported by the National Natural Science Foundation of China (Grant Nos. 82073934, 81872937, and 81673513).

Acknowledgments

None.

References

[1] Wang Y, Dan Y, Yang D, et al. The genus Anemarrhena Bunge: a review on ethnopharmacology, phytochemistry and pharmacology[J]. J Ethnopharmacol, 2014, 153(1): 42-60. doi: 10.1016/j.jep.2014.02.013

[2] Zhang M, Qu J, Gao Z, et al. Timosaponin AIII induces G2/M arrest and apoptosis in breast cancer by activating the ATM/Chk2 and p38 MAPK signaling pathways[J]. Front Pharmacol, 2021, 11: 601468. doi: 10.3389/fphar.2020.601468

[3] Lin Y, Zhao W, Shi W, et al. Pharmacological activity, pharmacokinetics, and toxicity of timosaponin AIII, a natural product isolated from Anemarrhena asphodeloides Bunge: a review[J]. Front Pharmacol, 2020, 11: 764. doi: 10.3389/fphar.2020.00764

[4] Zhou Z, Zhao W, Xiao Y, et al. Antiangiogenesis effect of timosaponin AIII on HUVECs in vitro and zebrafish embryos in vivo[J]. Acta Pharmacol Sin, 2020, 41(2): 260-269. doi: 10.1038/s41401-019-0291-z

[5] Zhou C, Yu T, Zhu R, et al. Timosaponin AIII promotes non-small-cell lung cancer ferroptosis through targeting and facilitating HSP90 mediated GPX4 ubiquitination and degradation[J]. Int J Biol Sci, 2023, 19(5): 1471-1489. doi: 10.7150/ijbs.77979

[6] Stern S, Kurian R, Wang H. Clinical relevance of the constitutive androstane receptor[J]. Drug Metab Dispos, 2022, 50(7): 1010-1018. doi: 10.1124/dmd.121.000483

[7] Honkakoski P. Searching for constitutive androstane receptor modulators[J]. Drug Metab Dispos, 2022, 50(7): 1002-1009. doi: 10.1124/dmd.121.000482

[8] Sueyoshi T, Kawamoto T, Zelko I, et al. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene[J]. J Biol Chem, 1999, 274(10): 6043-6646. doi: 10.1074/jbc.274.10.6043

[9] Goodwin B, Hodgson E, D'Costa DJ, et al. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor[J]. Mol Pharmacol, 2002, 62(2): 359-365. doi: 10.1124/mol.62.2.359

[10] Gerbal-Chaloin S, Daujat M, Pascussi JM, et al. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor[J]. J Biol Chem, 2002, 277(1): 209-217. doi: 10.1074/jbc.M107228200

[11] Wortham M, Czerwinski M, He L, et al. Expression of constitutive androstane receptor, hepatic nuclear factor 4α and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver[J]. Drug Metab Dispos, 2007, 35(9): 1700-1710. doi: 10.1124/dmd.107.016436

[12] Yoshinari K, Yoda N, Toriyabe T, et al. Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5′-flanking region[J]. Biochem Pharmacol, 2010, 79(2): 261-269. doi: 10.1016/j.bcp.2009.08.008

[13] Osabe M, Sugatani J, Fukuyama T, et al. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet[J]. Drug Metab Dispos, 2008, 36(2): 294-303. doi: 10.1016/S0169-409X(02)00077-7

[14] Maglich JM, Stoltz CM, Goodwin B, et al. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification[J]. Mol Pharmacol, 2002, 62(3): 638-646. doi: 10.1124/mol.62.3.638

[15] Yanagiba Y, Ito Y, Kamijima M, et al. Octachlorostyrene induces cytochrome P450, UDP-glucuronosyltransferase, and sulfotransferase via the aryl hydrocarbon receptor and constitutive androstane receptor[J]. Toxicol Sci, 2009, 111(1): 19-26. doi: 10.1093/toxsci/kfp130

[16] Burk O, Arnold KA, Geick A, et al. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression[J]. Biol Chem, 2005, 386(6): 503-513. doi: 10.1515/BC.2005.060

[17] Banerjee M, Robbins D, Chen TS. Targeting xenobiotic receptors PXR and CAR in human diseases[J]. Drug Discov Today, 2015, 20(5): 618-628. doi: 10.1016/j.drudis.2014.11.011

[18] Yang H, Wang H. Signaling control of the constitutive androstane receptor (CAR)[J]. Protein Cell, 2014, 5(2): 113-123. doi: 10.1007/s13238-013-0013-0

[19] Koike C, Moore R, Negishi M. Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes[J]. Mol Pharmacol, 2007, 71(5): 1217-1221. doi: 10.1124/mol.107.034538

[20] Shizu R, Osabe M, Perera L, et al. Phosphorylated nuclear receptor CAR forms a homodimer to repress its constitutive activity for ligand activation[J]. Mol Cell Biol, 2017, 37(10): e00649-16. doi: 10.1128/MCB.00649-16

[21] Mutoh S, Sobhany M, Moore R, et al. Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling[J]. Sci Signal, 2013, 6(274): ra31. doi: 10.1126/scisignal.2003705

[22] Zhao Y, Zhou J, Zhang M, et al. Cytotoxic steroidal saponins from the rhizome of Anemarrhena asphodeloides[J]. Steroids, 2020, 155: 108557. doi: 10.1016/j.steroids.2019.108557

[23] Mutoh S, Osabe M, Inoue K, et al. Dephosphorylation of threonine 38 is required for nuclear translocation and activation of human xenobiotic receptor CAR (NR1I3)[J]. J Biol Chem, 2009, 284(50): 34785-34792. doi: 10.1074/jbc.M109.048108

[24] Osabe M, Negishi M. Active ERK1/2 protein interacts with the phosphorylated nuclear constitutive active/androstane receptor (CAR; NR1I3), repressing dephosphorylation and sequestering CAR in the cytoplasm[J]. J Biol Chem, 2011, 286(41): 35763-35769. doi: 10.1074/jbc.M111.284596

[25] de Boussac H, Gondeau C, Briolotti P, et al. Epidermal growth factor represses constitutive androstane receptor expression in primary human hepatocytes and favors regulation by pregnane X receptor[J]. Drug Metab Dispos, 2018, 46(3): 223-236. doi: 10.1124/dmd.117.078683

[26] Jin Q, Wu J, Wu Y, et al. Optical substrates for drug-metabolizing enzymes: recent advances and future perspectives[J]. Acta Pharm Sin B, 2022, 12(3): 1068-1099. doi: 10.1016/j.apsb.2022.01.009

[27] Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation[J]. Pharmacol Ther, 2013, 138(1): 103-141. doi: 10.1016/j.pharmthera.2012.12.007

[28] Hedrich WD, Hassan HE, Wang H. Insights into CYP2B6-mediated drug-drug interactions[J]. Acta Pharm Sin B, 2016, 6(5): 413-425. doi: 10.1016/j.apsb.2016.07.016

[29] Robey RW, Pluchino KM, Hall MD, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer[J]. Nat Rev Cancer, 2018, 18(7): 452-464. doi: 10.1038/s41568-018-0005-8

[30] Chen J, Jia X, Wang H, et al. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway[J]. Int J Oncol, 2016, 48(5): 2063-2070. doi: 10.3892/ijo.2016.3423

[31] Dai J, He Y, Fang J, et al. In vitro evaluation of the interaction of seven biologically active components in Anemarrhenae rhizoma with P-gp[J]. Molecules, 2022, 27(23): 8556. doi: 10.3390/molecules27238556

[32] Negishi M, Kobayashi K, Sakuma T, et al. Nuclear receptor phosphorylation in xenobiotic signal transduction[J]. J Biol Chem, 2020, 295(45): 15210-15225. doi: 10.1074/jbc.REV120.007933

[33] Tzameli I, Pissios P, Schuetz EG, et al. The xenobiotic compound 1, 4-bis[2-(3, 5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR[J]. Mol Cell Biol, 2000, 20(9): 2951-2958. doi: 10.1128/MCB.20.9.2951-2958.2000

[34] Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy[J]. Nat Rev Cancer, 2004, 4(5): 361-370. doi: 10.1038/nrc1360

[35] Sabbah DA, Hajjo R, Sweidan K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors[J]. Curr Top Med Chem, 2020, 20(10): 815-834. doi: 10.2174/1568026620666200303123102

[36] Negishi M. Phenobarbital meets phosphorylation of nuclear receptors[J]. Drug Metab Dispos, 2017, 45(5): 532-539. doi: 10.1124/dmd.116.074872

[37] Carazo A, Dusek J, Holas O, et al. Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling[J]. Front Pharmacol, 2018, 9: 993. doi: 10.3389/fphar.2018.00993

[38] Zhang J, Huang W, Chua SS, et al. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR[J]. Science, 2002, 298(5592): 422-424. doi: 10.1126/science.1073502

[39] Huang W, Zhang J, Washington M, et al. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor[J]. Mol Endocrinol, 2005, 19(6): 1646-1653. doi: 10.1210/me.2004-0520

[40] Yamamoto Y, Moore R, Goldsworthy TL, et al. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice[J]. Cancer Res, 2004, 64(20): 7197-7200. doi: 10.1158/0008-5472.CAN-04-1459